查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1768680

全球尿路上皮癌治療市場：依類型、療法、最終用戶、地區、機會及預測，2018-2032

Global Urothelial Cancer Drugs Market Assessment, By Type, By Treatment, By End-user, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 232 Pages | 商品交期: 3-5個工作天內

價格

全球尿路上皮癌治療市場預計將從2024年的30.3億美元成長到2032年的60.9億美元，在2025-2032年的預測期內，年複合成長率為9.12%。全球尿路上皮癌治療市場的發展受到以下因素的推動：尿路上皮癌患病率的上升、免疫療法和標靶療法的快速應用、強大的研發投入、對早期診斷日益成長的認識、醫療基礎設施的改善以及有利的監管支持，這些因素有助於在全球範圍內提供更好的治療方案並改善患者的治療效果。

得益於免疫療法的多項進展、各種策略聯盟的建立以及市場醫療保健投資的不斷增加，全球尿路上皮癌治療市場迅速擴張。包括免疫檢查點抑制劑在內的聯合療法等新療法徹底改變非肌肉浸潤性膀胱癌的治療方法，改善患者預後，並在全球創造市場機會。

例如，2025年4月，《歐洲泌尿腫瘤學》發表了一篇關於免疫檢查點抑制劑治療肌肉層浸潤性膀胱癌的綜述。本報告強調了免疫療法的進步和不斷發展的治療方案推動的市場快速成長。

目錄

第1章 專案範圍與定義

第2章 研究方法

第3章 美國關稅的影響

第4章 執行摘要

第5章 全球尿路上皮癌藥物市場展望（2018-2032）

  • 市場規模分析與預測
    • 依價值
  • 市場佔有率分析與預測
    • 依類型
      • 尿路上皮癌
      • 鱗狀細胞癌癌症
      • 腺癌
    • 依治療方法
      • 化療
      • 免疫療法
      • 標靶治療
      • 合併藥物治療
    • 依最終用戶
      • 醫院
      • 癌症治療中心
      • 門診手術中心
      • 其他
    • 依地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東和非洲
    • 依公司市場佔有率分析（前五名及其他 - （依價值，2024年））
  • 2024年市場地圖分析
    • 依類型
    • 依治療方法
    • 依最終用戶
    • 依地區

第6章 北美尿路上皮癌治療市場展望，2018-2032

  • 市場規模分析與預測
    • 依價值
  • 市場佔有率分析與預測
    • 依類型
      • 尿路上皮癌
      • 鱗狀細胞癌
      • 腺癌
    • 依治療方法
      • 化療
      • 免疫療法
      • 標靶治療
      • 合併藥物治療
    • 依最終用戶
      • 醫院
      • 癌症治療中心
      • 門診手術中心
      • 其他
    • 市場佔有率國家
      • 美國
      • 加拿大
      • 墨西哥
  • 依國家的市場評估
    • 美國尿路上皮癌藥物市場展望，2018-2032
      • 市場規模分析與預測
      • 市場佔有率分析與預測
    • 加拿大
    • 墨西哥

第7章 歐洲尿路上皮癌藥物市場展望，2018-2032

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第8章 亞太地區尿路上皮癌藥物市場展望2018-2032

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第9章 2018-2032年南美尿路上皮癌藥物市場展望

  • 巴西
  • 阿根廷

第10章 2018-2032年中東及非洲尿路上皮癌藥物市場展望

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第11章 供需分析

第12章 進出口分析

第13章 波特五力分析

第14章 PESTLE 分析

第15章 定價分析

第16章 市場動態

  • 市場驅動因素
  • 市場挑戰

第17章 市場趨勢與發展

第18章 監理架構與創新

  • 監理審批
  • 臨床試驗

第19章 專利格局

第20章 個案研究

第21章 競爭格局

  • 頂級競爭矩陣五大市場領導者
  • 前五大公司的SWOT 分析
  • 市場十大主要參與者情勢
    • Pfizer, Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • F. Hoffmann La Roche Ltd.
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Sanofi SA
    • Eisai Co. Ltd.
    • Merck KGaA
    • UroGen Pharma, Inc.

第22章 策略建議

第23章 關於調查公司/免責聲明

Product Code: MX13613

Global urothelial cancer drugs market is projected to witness a CAGR of 9.12% during the forecast period 2025-2032, growing from USD 3.03 billion in 2024 to USD 6.09 billion in 2032. The global urothelial cancer drug market is driven by the increasing prevalence of urothelial cancers, rapid adoption of immunotherapy and targeted therapies, strong R&D investments, rising awareness for early diagnosis, improved healthcare infrastructure, and favorable regulatory support, which are contributing to better treatment options and improved patient outcomes worldwide.

The global urothelial cancer drug market is expanding rapidly due to multiple advances in immunotherapy, a variety of strategic partnerships, and an increase in healthcare investment in the market. New therapies, such as combination therapy that involves immune checkpoint inhibitors, are revolutionizing the treatment of non-muscle invasive bladder cancer and improving patient outcomes and providing market opportunities across the globe.

For instance, in April 2025, European Urology Oncology published a review on immune checkpoint inhibitors for muscle-invasive bladder cancer. This highlighted rapid market growth fueled by advances in immunotherapy and evolving treatment options.

Increased Incidence Accelerates Growth in Urothelial Cancer Drug Market

Urothelial cancer incidence is on the rise and this in turn is affecting the urothelial cancer drugs market globally. As more people are diagnosed every year, many of whom are attributable to the aging population, smoking and environmental risk factors, the demand for products, either new products or improvements on existing products, is increasing rapidly. A target patient population that continues to flourish is pushing pharmaceutical companies to hasten research and development for identifying therapeutic targets and devising novel immunotherapies to address emerging clinical needs. Additionally, the healthcare system is under pressure to take on any new drug that will increase survival and quality of life for the emerging patient population.

For instance, according to the American Cancer Society, in 2025, there were projected to be 84,870 new cases of bladder cancer in the United States (about 65,080 in men and 19,790 in women) along with approximately 17,420 deaths, underscoring the growing need for effective urothelial cancer treatments.

Therapeutic and Diagnostic Advancement Fuel Urothelial Cancer Drug Market Growth

The global urothelial cancer drug market remains in growth, primarily due to improvements in treatment and discovery for urothelial cancer. Precision therapies and state-of-the-art diagnostics are evolving the entire industry landscape to improve outcomes and create a new vantage point for reasons for adoption. Targeted treatments such as FGFR inhibitors offer personalized treatments for patients identified with inherited genetic alterations to address their cancer, while immunotherapy combinations are increasingly replacing frontline therapies due to their superior outcomes relative to traditional chemotherapy. Simultaneously, novel non-invasive diagnostic tools, such as urine-based genomic assays, demonstrate unprecedented accuracy in early malignancy detection. This advancement improves treatment options and enables proactive care planning, while expanding market opportunities through earlier intervention. In sum, all these advances are expanding the population of patients that can be addressed and driving demand for advanced therapeutic agents globally.

For instance, in May 2025, the Scottish Medicines Consortium (SMC) approved BALVERSA (erdafitinib), marking a major milestone as the first licensed bladder cancer therapy to specifically target FGFR3 alterations.

Immunotherapy Leads the Global Urothelial Cancer Drug Market

Immunotherapy has become the dominant segment of the global urothelial cancer drugs market, revolutionizing treatment paradigms by harnessing the immune system to target cancer cells more effectively and with reduced toxicity compared to conventional therapies. This utilizes patient outcomes to improve where previous therapies have failed. The presence of an ever-growing pipeline of immunotherapeutic and continued regulatory approvals provides significant growth in the market and attracts significant capital as well as innovation. Immunotherapy is competitive and disruptive in ways that hospitals and medical professionals did not expect. In addition to changing treatment modalities, many treatments extend life and improve quality of life, which in turn towards personalized cancer care, or care that is specific to a patient's unique situation.

For instance, in April 2024, ImmunityBio launched ANKTIVA (nogapendekin alfa inbakicept), a first-in-class IL-15 receptor agonist, after receiving FDA approval for the treatment of BCG-unresponsive non-muscle invasive urothelial cancer.

North America Dominates the Urothelial Cancer Drugs Market Size

North America, especially the United States, is the largest geographic area for the global urothelial cancer drugs market, due to an innovative healthcare system with early adoption of new therapies and a very conducive regulatory environment for good clinical practice. In addition, the North America urothelial cancer drugs market is projected to surge owing to the existence of pharmaceutical companies, specialty oncology care is widely available, ample research funding is available, and innovators have and continue to develop treatment options, coupled with easy accessibility of advancing bladder cancer care. Regulatory authorities, such as the US Food and Drug Administration (FDA), also have a major impact on the rate of innovations, regularly using accelerated approval pathways for innovative immunotherapies and targeted drugs through various priority review designations. This expedited access to innovation in the United States market will translate to first access for clinicians to innovative therapies globally as they will enter practice sooner.

For example, in March 2024, the FDA approved nivolumab (Opdivo) in combination with cisplatin and gemcitabine for first-line treatment of adults with unresectable or metastatic urothelial carcinoma. This approval, based on the large CheckMate 901 Phase III trial, was granted priority review and introduced the first immunotherapy plus chemotherapy regimen into standard care.

Impact of U.S. Tariffs on Global Urothelial Cancer Drugs Market

Rising Manufacturing Costs: Tariffs on the APIs and finished drugs used to produce oral cancer treatments raise the manufacturing costs.

Rising Drug Prices: Patients and payers will be faced with increased costs of the treatments because of the increased manufacturing costs likely to be passed along to them.

Increased Pressure on Generic Drug Access: Generic producers operate at very limited margins and may respond by cutting back on the amount of drugs they produce or, more problematically, not producing the drugs at all, reducing access to the drugs.

Supply Chain Disruption: Import dependence means tariffs will have an impact on supply chains and possibly shortages and delays.

Time Delay on the Domestic Manufacturing Response: Building new manufacturing facilities takes multiple years, and tariffs are a short-term solution.

Restricted Patient Access: Increased prices mean that access to treatment is affected, particularly for low-income or uninsured patients.

Impact on Clinical Trial Research: Instability in drug supply can slow down or disrupt clinical research on oral medications due to difficulty accessing consistent supplies.

Key Players Landscape and Outlook

Growing the global urothelial cancer drugs market are the major pharmaceutical companies who are utilizing innovative therapies, collaborations and personalized models of treatment. The top leaders in the field are manipulating non-invasive treatment options along with immunotherapy and combination treatment options to address early treatment and resistant urothelial cancers. Companies are also responding to the unmet need of patients with non-muscle invasive bladder cancer with options that are non-invasive intravesical therapies. By forming partnerships, licensing arrangements, or co-development and agreements, these companies are expediting innovations in urothelial cancers and delivering to many regions of the world. These strategies are enhancing patient outcomes and changing current treatment options.

For example, in April 2025, Pfizer, Inc. announced that its immunotherapy drug sasanlimab, combined with BCG, significantly improved event-free survival in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, demonstrating how targeted innovation by key players is driving market growth and advancing care standards.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Urothelial Carcinoma
      • 5.2.1.2. Squamous Cell Carcinoma
      • 5.2.1.3. Adenocarcinoma
    • 5.2.2. By Treatment
      • 5.2.2.1. Chemotherapy
      • 5.2.2.2. Immunotherapy
      • 5.2.2.3. Targeted Therapy
      • 5.2.2.4. Combination Drug Therapy
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals
      • 5.2.3.2. Cancer Treatment Centers
      • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Type
    • 5.3.2. By Treatment
    • 5.3.3. By End-user
    • 5.3.4. By Region

6. North America Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Type
      • 6.2.1.1. Urothelial Carcinoma
      • 6.2.1.2. Squamous Cell Carcinoma
      • 6.2.1.3. Adenocarcinoma
    • 6.2.2. By Treatment
      • 6.2.2.1. Chemotherapy
      • 6.2.2.2. Immunotherapy
      • 6.2.2.3. Targeted Therapy
      • 6.2.2.4. Combination Drug Therapy
    • 6.2.3. By End-user
      • 6.2.3.1. Hospitals
      • 6.2.3.2. Cancer Treatment Centers
      • 6.2.3.3. Ambulatory Surgical Centers
      • 6.2.3.4. Others
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Urothelial Cancer Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Type
          • 6.3.1.2.1.1. Urothelial Carcinoma
          • 6.3.1.2.1.2. Squamous Cell Carcinoma
          • 6.3.1.2.1.3. Adenocarcinoma
        • 6.3.1.2.2. By Treatment
          • 6.3.1.2.2.1. Chemotherapy
          • 6.3.1.2.2.2. Immunotherapy
          • 6.3.1.2.2.3. Targeted Therapy
          • 6.3.1.2.2.4. Combination Drug Therapy
        • 6.3.1.2.3. By End-user
          • 6.3.1.2.3.1. Hospitals
          • 6.3.1.2.3.2. Cancer Treatment Centers
          • 6.3.1.2.3.3. Ambulatory Surgical Centers
          • 6.3.1.2.3.4. Others
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Urothelial Cancer Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Import Export Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Regulatory Approvals
  • 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Pfizer, Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. GlaxoSmithKline plc
    • 21.3.3. Novartis AG
    • 21.3.4. F. Hoffmann La Roche Ltd.
    • 21.3.5. Astellas Pharma Inc.
    • 21.3.6. AstraZeneca plc
    • 21.3.7. Sanofi SA
    • 21.3.8. Eisai Co. Ltd.
    • 21.3.9. Merck KGaA
    • 21.3.10. UroGen Pharma, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 3. Global Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 4. Global Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 5. Global Urothelial Cancer Drugs Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 8. North America Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 9. North America Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 10. North America Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 13. United States Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 14. United States Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 15. Canada Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 17. Canada Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 18. Canada Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 19. Mexico Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 21. Mexico Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 22. Mexico Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 23. Europe Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 25. Europe Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 26. Europe Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 27. Europe Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 30. Germany Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 31. Germany Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 32. France Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 34. France Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 35. France Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 36. Italy Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 38. Italy Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 39. Italy Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 40. United Kingdom Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 42. United Kingdom Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 43. United Kingdom Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 44. Russia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 46. Russia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 47. Russia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 48. Netherlands Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 50. Netherlands Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 51. Netherlands Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 52. Spain Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 54. Spain Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 55. Spain Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 56. Turkey Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 58. Turkey Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 59. Turkey Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 60. Poland Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 62. Poland Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 63. Poland Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 64. South America Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 66. South America Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 67. South America Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 68. South America Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 71. Brazil Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 72. Brazil Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 73. Argentina Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 75. Argentina Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 76. Argentina Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 77. Asia-Pacific Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 79. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 80. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 81. Asia-Pacific Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 82. India Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 84. India Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 85. India Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 86. China Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 88. China Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 89. China Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 90. Japan Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 92. Japan Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 93. Japan Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 94. Australia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 96. Australia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 97. Australia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 98. Vietnam Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 100. Vietnam Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 101. Vietnam Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 102. South Korea Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 104. South Korea Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 105. South Korea Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 106. Indonesia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 108. Indonesia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 109. Indonesia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 110. Philippines Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 112. Philippines Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 113. Philippines Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 114. Middle East & Africa Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 116. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 117. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 118. Middle East & Africa Urothelial Cancer Drugs Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 121. Saudi Arabia Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 122. Saudi Arabia Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 123. UAE Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 125. UAE Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 126. UAE Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 127. South Africa Urothelial Cancer Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Urothelial Cancer Drugs Market Share (%), By Type, 2018-2032F
  • Figure 129. South Africa Urothelial Cancer Drugs Market Share (%), By Treatment, 2018-2032F
  • Figure 130. South Africa Urothelial Cancer Drugs Market Share (%), By End-user, 2018-2032F
  • Figure 131. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024